1NKILT Therapeutics

1NKILT Therapeutics is a biotechnology company focused on developing next-generation natural killer (NK) cell therapies for the treatment of cancer. The company's proprietary platform is designed to enhance the killing capacity and persistence of NK cells, specifically targeting the NKG2D pathway to overcome the immunosuppressive environment of solid tumors. By engineering NK cells with improved homing and activation profiles, 1NKILT aims to provide off-the-shelf cellular immunotherapies that are more effective and accessible than current T-cell based treatments. The company is currently advancing its lead programs through pre-clinical development with a focus on both liquid and solid malignancies.